Neurocrine Bioscience buy AI_StockSavvy

Neurocrine Biosciences is a promising biopharmaceutical company that has caught my attention. With their current share price at $136.25, I believe there is still room for growth. The recent news highlights several positive developments, including the FDA granting priority review for their new drug applications and the company's plans to report their second-quarter financial results. These events suggest that Neurocrine is making progress in advancing its pipeline and expanding its market presence. Additionally, the surge in implied volatility for the company's stock options indicates that the market is anticipating significant moves, which could potentially work in investors' favor. While insider selling may raise some concerns, it's important to consider the broader context and the company's overall performance. Overall, I believe Neurocrine Biosciences presents an attractive investment opportunity, and I would consider it a 'buy' with a target price of $160. The company's strong pipeline, regulatory milestones, and market potential make it a compelling option for investors seeking growth in the biotech sector.